New data provides researchers with aggregated, anonymized specialty prescribing habits across brands and diseases.
Clarivate has released German hospital prescribing insights within The Clarivate Patient Data Intelligence (CPDI), which includes new aggregated, anonymized data product to provide clarity on this market’s trends, patient characteristics, and specialty prescribing habits across brands and diseases.
The self-service CPDI platform positions Clarivate as a leading provider of real-world data solutions in Europe, as well as providing pharma companies the ability to identify specialties they are most interested in and optimize commercial targeting in key European markets, including Italy, France, Spain and Germany.
Zoe Barker, Vice President of Product, Clarivate, said, in a press release, "Significant investment of resources is required to analyze real world data products, particularly to understand the European market landscape, patient behavior, and prescribing habits. Such investment can delay the success of drug launches. With the addition of German hospital prescribing insights, Clarivate continues to deliver market leading intelligence that empowers life science and healthcare organizations to create a healthier tomorrow."
Reference: Clarivate Enhances Patient Data Intelligence Solution with Addition of German Hospital Prescribing Insights. London, July 27, 2023 /PRNewswire.
FDA Approves Dupixent as First-Ever Biologic Treatment for Chronic Obstructive Pulmonary Disease
September 27th 2024Dupixent was found to significantly reduce the rate of moderate to severe exacerbations of chronic obstructive pulmonary disease, according to data from the Phase III BOREAS and NOTUS trials.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.